RESEARCH ARTICLE

The Synthetic β-Nitrostyrene Derivative CYT-Rx20 Inhibits Esophageal Tumor Growth and Metastasis via PI3K/AKT and STAT3 Pathways

Wen-Chin Chiu1, Yi-Chen Lee2, Yu-Han Su3, Yen-Yun Wang4, Chun-Hao Tsai5, Yi-An Hou6, Chie-Hong Wang5, Ying-Fong Huang7, Chih-Jen Huang8, Shah-Hwa Chou1, Pei-Wen Hsieh9,10, Shyng-Shiou F. Yuan3,4,5,11*

1 Division of Thoracic Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan,
2 Department of Anatomy, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan,
3 Translational Research Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan,
4 Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan,
5 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan,
6 Department of Respiratory Therapy, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan,
7 Department of Nuclear Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan,
8 Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan,
9 Graduate Institute of Natural Products, School of Traditional Chinese Medicine and Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan,
10 Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan, Taiwan,
11 Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

* yuanssf@kmu.edu.tw

Abstract

The β-nitrostyrene family have been implicated for anti-cancer property. However, the pharmacological role of β-nitrostyrene in esophageal cancer remain unclear. Here, a β-nitrostyrene derivative, CYT-Rx20, was synthesized and assessed for its anti-cancer activities and underlying mechanism in esophageal cancer. CYT-Rx20 induced cytotoxicity in esophageal cancer cells by promoting apoptosis through activation of caspase cascade and poly(ADP-ribose) polymerase (PARP) cleavage. Besides, CYT-Rx20 inhibited esophageal cancer cell migration and invasion by regulating the expression of epithelial to mesenchymal transition (EMT) markers. CYT-Rx20 decreased cell viability and migration through suppression of the PI3K/AKT and STAT3 pathways. Of note, the cytotoxicity and anti-migratory effect of CYT-Rx20 were enhanced by co-treatment with SC79 (AKT activator) or colivelin (STAT3 activator), suggesting the dependency of esophageal cancer cells on AKT and STAT3 for survival and migration, an oncogene addiction phenomenon. In xenograft tumor-bearing mice, CYT-Rx20 significantly reduced tumor growth of the implanted esophageal cancer cells accompanied by decreased Ki-67, phospho-AKT, and phospho-STAT3 expression. In orthotopic esophageal cancer mouse model, decreased tumor growth and lung metastasis with reduced Ki-67 and phospho-STAT3 expression were observed in mice treated with CYT-Rx20. Together, our results suggest that CYT-Rx20 is a potential β-nitrostyrene-based anticancer compound against the tumor growth and metastasis of esophageal cancer.
Introduction

Esophageal cancer is the eighth most common malignancies worldwide including eastern Asia with the overall five year survival rate ranging from 15% to 25% [1–3]. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are the two major subtypes of esophageal cancer with ESCC accounting for more than 90% of esophageal cancer cases and characterized by frequent relapses and metastatic capabilities [4]. Despite advance in early detection and treatment with concurrent chemoradiation therapy (CCRT) alone or as an adjunct to surgery [5], esophageal cancer remains a major challenge and requires more effective therapeutic strategies.

The β-nitrostyrene family compounds have been recognized for anti-cancer, anti-microbial, anti-inflammatory, and anti-platelet activities [6–11]. β-nitrostyrene derivatives induced pro-apoptotic effect through inhibition of protein tyrosine phosphatases (PTPs) and phosphatases 2A (PP2A) [12,13] and inhibited the growth of cancer cells derived from stomach and immune responses of macrophages [6]. In addition, they induced the apoptosis in Burkitt’s lymphoma derived cells via chromatin condensation and membrane blebbing [14]. The potent effects of β-nitrostyrene derivatives on inhibiting the TNFα-induced NF-κB survival pathway in a truncated retinoid X receptor α (tRXRα)-dependent manner resulted in a synergistic effect of β-nitrostyrene derivatives and TNFα on inducing breast cancer cell apoptosis [15]. Moreover, two β-nitrostyrene derivative compounds NTS1 and NTS2 induced apoptosis through cytochrome c release from mitochondria to cytosol and caspase activation in Ehrlich ascitic tumor cells [16]. Recently, the inhibitory effect of 3,4-methylenedioxy-β-nitrostyrene on breast cancer cell adhesion and migration was demonstrated by suppressing β1 integrin and surface protein disulfide isomerase [17].

Our previous studies demonstrated that CYT-Rx20 (3α-hydroxy-4α-methoxy-β-methyl-β-nitrostyrene), a synthetic derivative of β-nitrostyrene, tended to increase the anti-platelet activity and induces breast cancer cell death and autophagy through ROS-mediated MEK/ERK pathway [10,18]. However, the pharmacological effects and molecular mechanism of CYT-Rx20’s action in esophageal cancer remain unknown. In this study, the anti-esophageal cancer activity of CYT-Rx20 is explored by studying its biological effects and the underlying mechanisms in vitro and in vivo.

Materials and Methods

Materials

CYT-Rx20 was synthesized by methods that have been previously described [11]. Chemotherapeutic agents used in this study included 5-Fluorouracil (5-FU) (Mayne Pharma Pty Ltd, Mulgrave, Victoria, Australia). SC79 was purchased from Tocris Biosciences (Bristol, UK). Colivelin was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies recognizing AKT, phospho-STAT3 (Tyr705), caspase 9, Cdc25C, and cleaved poly (ADP-ribose) polymerase (PARP) (Asp214) were obtained from Cell Signaling Technology (Danvers, MA). Cyclin B1, phospho-p21 (Tyr 467), phospho-Akt (Ser473), p85, STAT3, ZO-1, ZEB1, Snail, and β-actin antibodies were purchased from GeneTex (Irvin, CA). Slug antibody was obtained from ThermoFisher (Wilmington, DE). Caspase 3 and caspase 8 antibodies were purchased from Novus (Irvin, CA). Antibodies against phospho-p21 (Thr145), N-cadherin and α-tubulin were obtained from Abcam (Cambridge, MA). Ki-67 antibody was obtained from Biorbyt (Riverside, UK). Other chemicals were obtained from Sigma (St. Louis, MO).
Cell Culture

The esophageal cancer cell line (KYSE70) was kindly provided by Dr. Yi-Ching Wang (Department of Pharmacology, National Cheng Kung University, Tainan, Taiwan). Human ESCC cell line (TE8) was kindly provided by Dr. Mien-Chie Hung (MD Anderson Cancer Center, Houston, TX). Normal human esophageal squamous cell line (HET-1A) was kindly provided by Dr. Pei-Jung Lu (Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan). KYSE70 was cultured in RPMI1640 medium (Invitrogen, Carlsbad, CA). TE8 cells were cultured in DMEM/F12 medium (Invitrogen, Carlsbad, CA). The HET-1A cell line was cultured in BEBM (Bronchial/Tracheal Epithelial Cell Basal Medium; CELL Applications, San Diego, CA). All the medium were supplemented with 10% (v/v) fetal bovine serum, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2.5 μg/mL amphotericin B (Biological Industries, Haemek, Israel). All cells were grown in a 5% CO₂ incubator at 37˚C.

XTT colorimetric assay

Cell viability of KYSE70 and TE8 cells treated with CYT-Rx20 was determined by tetrazolium salt 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT) assay (Roche Applied Science, Indianapolis, IN). Cells were seeded at the density of 5×10³ cells/well in 96-well plates and allowed to grow for additional times. The cell culture medium was removed and XTT assay was carried out by the methods previously described [19]. Three independent experiments with four replicates in each were performed.

Annexin V/PI apoptosis assay

Annexin V/PI apoptosis detection kit was purchased from BD Biosciences (Franklin Lakes, NJ) and detailed procedure was followed according to the manufacturer’s instructions. Briefly, after treatment with CYT-Rx20 for 48 h, the cells were collected and washed twice with cold PBS and then adjusted to 5×10⁵ cells/500 μl in binding buffer containing annexin V-FITC (1 μg/ml) and PI before analysis by flow cytometry (BD Biosciences).

Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay

Cells were treated with the indicated concentrations of CYT-Rx20 for 48 h and then stained for apoptotic cells using the DeadEnd Colorimetric TUNEL system from Promega (Madison, WI). The procedures were followed according to a previous described report [20].

Fluorescence-activated cell sorting (FACS) analysis

FACS analysis was applied to analyze the cell cycle distribution. KYSE70 and TE8 cells were treated with CYT-Rx20 and plated on six-well plates (Corning Life Sciences, Corning, NY). Cells were trypsinized by 1% trypsin-EDTA (Invitrogen, Carlsbad, CA), fixed in 75% ethanol (Sigma, St. Louis, MO) and stored at -20˚C for at least 16 h. Before analysis, cells were stained for 30 min at 37˚C with PBS containing 50 μg/mL propidium iodide and 4 kU/mL RNase (BD Biosciences, San Jose, CA). The DNA contents were measured by FACScan flow cytometer (BD Biosciences, Franklin Lakes, NJ) and cell cycle distribution was calculated using Winmd 2.8 software (J. Trotter, Scripps Research Institute, La Jolla, CA).

Immunoblotting analysis

The whole cell extracts were collected by lysing cells in the buffer containing 50 mM Hepes, 6 mM EDTA, and 1% Triton X-100 supplemented with phosphatase inhibitor (Sigma, St. Louis,
MO) and complete protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN). Total protein was separated by centrifugation at 12,000g for 20 min at 4°C. The protein concentration was determined using the Bradford assay (Bio-Rad, Hercules, CA) with BSA as a standard. Equal amounts of proteins were subjected to 10% SDS-PAGE and transferred onto nitrocellulose membranes (Pall corporation, East Hills, NY). The immunoblot analysis for protein expression was performed as described previously [19]. The chemiluminescent signal was captured by a ChemiDoc™ XRS+ System (Bio-Rad Laboratories, Hercules, CA) and quantified with Image Lab software (Bio-Rad Laboratories, Hercules, CA).

Cell migration and invasion assays

Cell migration was estimated by a modified Boyden chamber assay. Cells (5×10^4 cells/well) suspended in 2% FBS medium were placed in the upper chamber of 8-μm pore size transwells (24-well, Corning Life Sciences, Corning, NY), and medium with 10% FBS was added to the lower chamber. After incubation for 48 hours, the unmigrated cells were removed from the upper surface of the membrane, and the migrated cells on the lower surface of the membrane were fixed in 100% methanol and stained with Giemsa stain (Sigma, St. Louis, MO). The cell migration was determined by counting the number of the migrated cells under a microscope at ×100 magnification. Four visual fields were chosen randomly and the average area of migrated cells in the four fields was calculated for each group. In vitro cell invasion assay was determined using transwells with 8 μm pores coated with Matrigel (Corning Life Sciences, Corning, NY) with the same protocol of cell migration as described above.

Anchorage-independent soft agar assay

Soft agar colony formation assay was performed according to the previous study [19]. Briefly, medium mixed with 0.5% agar (Sigma) was paved onto a 24-well plate (Corning Life Sciences, Corning, NY) and allowed to solidify. The dishes were overlaid with 5×10^3 CYT-Rx20-treated KYSE70 cells in medium with 5% fetal bovine serum and 0.3% agarose. Cultures were allowed to form colonies for 28 days and replenished with medium every 3–4 days. Colonies were stained with 0.005% crystal violet (Sigma, St. Louis, MO) and then were counted using a dissecting microscope (Nikon, Tokyo, Japan).

In vivo tumor xenograft study

All experiments involving mice were performed according to the guidelines of the Animal Committee and approved by the Institutional Animal Care and Use Committee (IACUC no. 102009) of Kaohsiung Medical University, Taiwan. Six-week-old female immunodeficient BALB/cAnN.Cg-Foxn1tm1/CrlNarl mice, obtained from the National Laboratory Animal Center of Taiwan, were used in this study. The mice were housed 2–3 animals per cage with sterilized stainless steel cover and bedding, under 12 h light/dark cycle, 22 ± 2°C room temperature, and 40–60% relative humidity. Food and drinking water were provided ad libitum. The mice were then subcutaneously injected with 5 × 10^6 KYSE70 cells at the right and left flank. When tumors became visible (approximately an average diameter of 3 mm), the mice were intraperitoneally injected with CYT-Rx20, dissolved in DMSO and then diluted with 100 μL normal saline (0.1% DMSO), at 5 μg/g body weight or 25 μg/g body weight three times a week (n = 10 for each group). The control mice were injected with 0.1% DMSO in normal saline only. Tumor sizes were measured by using calipers every week and tumor volumes were calculated according to a standard formula: (width^2 x length)/2. After 4 weeks, the mice were sacrificed by deep anesthesia with isoflurane (Baxter, Deerfield, IL) and, after tumor weight was measured, tumor and mouse organs were harvested for histological examination.
Orthotopic esophageal cancer mouse model

Six-week-old female immunodeficient BALB/cAnN.Cg-\(\text{Foxn1}^{\text{nu}}\)/CrlNarl mice were obtained from the National Laboratory Animal Center of Taiwan. The mice were housed 2–3 animals per cage in pathogen free conditions, under 12 h light/dark cycle, 22 ± 2°C room temperature, and 40–60% relative humidity with ad libitum food and drinking water. Orthotopic esophageal cancer model was performed according to a previous study [21]. A skin incision was made in the middle of the upper abdomen from the xiphoid process. The liver was raised up, and then the stomach was pulled down so that the abdominal esophagus was seen. A syringe with a 31G needle was inserted into the abdominal esophagus and injected with \(1 \times 10^6\) luciferase-expressing KYSE70 cells. Then, the mice were intraperitoneally injected with either 0 μg/g or 5 μg/g of CYT-Rx20 dissolved in DMSO with 100 μl normal saline (0.1% DMSO) three times a week (n = 4–5 for each group). At 4 weeks after tumor inoculation, the mice were analyzed for the presence of bioluminescent signals by Xenogen IVIS Spectrum in vivo imaging system (Caliper Life Sciences, Hopkinton, MA). The mice were anesthetized with isoflurane (Baxter, Deerfield, IL) using a XGI-8 Gas Anesthesia System (Caliper Life Sciences, Hopkinton, MA) followed by intraperitoneal injection of D-luciferin (150 mg/kg; PerkinElmer, Waltham, MA) for the detection of luciferase expression. The optical images were acquired and analyzed by Xenogen Living Image software (Caliper Life Sciences, Hopkinton, MA). Then, the mice were sacrificed by deep anesthesia with isoflurane (Baxter, Deerfield, IL), and its main esophageal tumor and potentially metastatic organs were harvested for histological examination. The animal study was approved by the Institutional Animal Care and Use Committee (IACUC No. 102009) of Kaohsiung Medical University, Taiwan.

Immunohistochemical Analysis

Immunohistochemical (IHC) staining for Ki-67, phospho-AKT, phospho-STAT3, and cleaved caspase-3 was performed on a Leica Bond-Max autostainer (Leica Microsystems, Bannockburn, IL). Sections cut from formalin-fixed, paraffin-embedded tissue blocks were baked at 60°C for 1 h, then deparaffinized in Bond Dewax solution at 72°C for 30 min and rehydrated in Bond Wash solution. Heat-induced antigen retrieval was carried out with Bond Epitope Retrieval solution 2 for 20 min at 100°C and peroxide block placement on the slides for 5 min at room temperature. Slides were then incubated with antibodies at a dilution of 1:200–500 for 30 min and Post Primary reagent for 8 min at room temperature. Antibody detection was carried out with the Bond Polymer placement for 8 min and color development with DAB (3,3’-diaminobenzidine tetrahydrochloride) as a chromogen for 5 min at room temperature. Slides were counterstained with hematoxylin for 5 min, followed by mounting of the slides and then the images of IHC-stained sections were captured by a Nikon E-800M microscope (Tokyo, Japan) and processed by Nikon NIS-Elements Version 4.30 software (Tokyo, Japan). The results for Ki-67, phospho-AKT, and phospho-STAT3 staining were determined by two independent experts under the same condition. For quantification, the sections of each immunostaining were scored using the method of histochemical score (H-score), which was calculated as the product of percentage of stained cells and intensity of staining [22,23].

Statistical analysis

Data are given as means ± S.E.M. and all experiments were repeated at least three times independently. All statistical analyses were performed using the SPSS 20.0 statistical software for PC (SPSS, Chicago, IL) and \(P\) values less than 0.05 were considered statistically significant. Statistical analysis between the control and CYT-Rx20 group was performed using two-sided
Student’s t-test. One-way ANOVA, combined with Tukey’s multiple-comparison test, was used to evaluate the statistical significance of differences between three or more groups.

Results
The synthetic β-nitrostyrene derivative CYT-Rx20 induced esophageal cancer cell death

The cytotoxicity of a β-nitrostyrene derivative, CYT-Rx20 (Fig 1A), on human esophageal cancer cells was analyzed by XTT assay. CYT-Rx20 exhibited the potent cytotoxic effect against esophageal cancer cells (KYSE70 and TE8, Fig 1B) in comparison with the HET-1A normal esophageal squamous cell line (S1 Fig). The inhibitory concentrations of IC50 after 48 h treatment with CYT-Rx20 on two esophageal cancer cell lines, KYSE70 and TE8, were 5.16 ± 0.21 and 3.07 ± 0.04 μg/ml, respectively (Table 1), compared to the HET-1A normal esophageal cells (6.05 ± 2.35 μg/ml). CYT-Rx20 showed a higher potency of cytotoxicity on esophageal cancer cells than the clinically used drug, 5-Fu (Table 1). Next we analyzed cell apoptosis by Annexin V/PI staining after CYT-Rx20 treatment for 48 h. We observed statistically significantly higher in CYT-Rx20-treated KYSE70 and TE8 cells compared with untreated control cells (KYSE70: 38.4 ± 6.7% vs. 2.9 ± 1.6%, P < 0.01; TE8: 41.8 ± 0.2% vs. 5.0 ± 1.3%, P < 0.001) (Fig 1C). The apoptotic cell death induced by CYT-Rx20 was further evidenced by TUNEL staining (KYSE70: 44.7 ± 11.4% vs. 1.7 ± 1.5%, P < 0.01; TE8: 52.4 ± 19.1% vs. 1.2 ± 0.3%, P < 0.05) (Fig 1D). Further, CYT-Rx20 treatment decreased the protein expression of pro-caspase-8, 9, 3, and increased the levels of cleaved PARP (Fig 1E).

Effect of CYT-Rx20 on esophageal cancer cell migration and invasion in vitro

Directed migration of cells in vitro, measured in a modified Boyden chamber assay as the area of migrated cells after CYT-Rx20 treatment for 48 h, showed a reduced motility in KYSE70 and TE8 cells with the indicated concentrations of CYT-Rx20 compared with that of untreated control (KYSE70: 0.33 ± 0.03 fold vs. 1.00 ± 0.02 fold, P < 0.001; TE8: 0.39 ± 0.09 fold vs. 1.00 ± 0.10 fold, P < 0.01) (Fig 2A). In Matrigel-covered transwell assay, KYSE70 and TE8 cells with CYT-Rx20 treatment at the dosages that do not cause obvious cell death showed attenuated cell invasion after 48 h of incubation compared with the control group (KYSE70: 0.26 ± 0.07 fold vs. 1.14 ± 0.16 fold, P < 0.001; TE8: 0.07 ± 0.01 fold vs. 1.00 ± 0.12 fold, P < 0.001) (Fig 2B). A crucial event in cancer cell migration and invasion is the epithelial-mesenchymal conversions, and the expression of epithelial to mesenchymal transition (EMT) markers is required for the early steps of metastasis [24,25]. We examined the protein levels of epithelial marker (ZO-1) and mesenchymal markers (N-cadherin, ZEB1, Slug, Snail) in esophageal cancer cells by immunoblotting analysis and found that the level of ZO-1 was markedly increased in KYSE70 and TE8 cells with the indicated concentrations of CYT-Rx20 compared with the control (P < 0.05 in KYSE70; P < 0.001 in TE8) (Fig 2C). In contrast, the expression of N-cadherin, ZEB1, Slug, and Snail after CYT-Rx20 incubation was decreased in KYSE70 and TE8 cells compared with control cells (Fig 2C).

Involvement of PI3K/AKT and STAT3-mediated pathways in CYT-Rx20-suppressed cell viability and migration

Recent studies have shown that activation of Akt and STAT3 in tumor cells enhances cell migration and growth [26,27]. As shown in Fig 3A, decreased protein expression of phosphop85, phospho-AKT, and phospho-STAT3 was observed in esophageal cancer cells after
CYT-Rx20 Inhibits Esophageal Tumor Growth and Metastasis

Figure A: Chemical structure of CYT-Rx20.

Figure B: Graph showing cell viability of KYSE70 and TE-8 cells treated with different concentrations of CYT-Rx20.

Figure C: Flow cytometry analysis of Annexin V positive cells in KYSE70 and TE-8 cells treated with different concentrations of CYT-Rx20.

Figure D: Flow cytometry analysis of TUNEL-positive cells in KYSE70 and TE-8 cells treated with different concentrations of CYT-Rx20.

Figure E: Western blot analysis of Caspase-8, Caspase-9, Caspase-3, Cleaved PARP, and α-tubulin expression in KYSE70 and TE-8 cells treated with different concentrations of CYT-Rx20.
CYT-Rx20 treatment, while the total form of p85, AKT, and STAT3 was not significantly altered by CYT-Rx20. To further investigate the role of AKT and STAT3 pathways in CYT-Rx20-reduced cell viability and migration, AKT activator SC79 and STAT3 activator colivelin were applied. CYT-Rx20-treated esophageal cancer cells, when co-treated with AKT activator SC79 or STAT3 activator colivelin, significantly suppressed the viability in KYSE70 and TE8 cells (Fig 3B and 3C). Similar inhibitory effect on cell migration was observed after co-treatment of CYT-Rx20 and the above activators (Fig 3D and 3E).

**CYT-Rx20 inhibited in vitro anchorage-independent cell growth and in vivo xenograft tumor growth**

The inhibitory effect of CYT-Rx20 on in vitro anchorage-independent tumor growth of esophageal cancer cells was evaluated. The results of soft agar assay showed that CYT-Rx20 (1.25, 2.5 or 5 μg/ml) dose-dependently suppressed the anchorage-independent tumor growth of esophageal cancer cells (Fig 4A). To investigate the anti-cancer activity of CYT-Rx20 in vivo, the nude mice model with subcutaneous xenograft was employed. As shown in Fig 4B, KYSE70 tumor growth was significantly suppressed by CYT-Rx20 treatment in comparison with the untreated control group. After 4 weeks of CYT-Rx20 treatment, the average tumor volumes for the untreated control, CYT-Rx20 (5 μg/g body weight), and CYT-Rx20 (25 μg/g body weight) groups were 486.40 ± 47.59, 174.10 ± 17.83, and 99.13 ± 13.36 mm³, respectively (Fig 4B), and the average tumor weights were 0.27 ± 0.05, 0.13 ± 0.01, and 0.09 ± 0.01 g, respectively (Fig 4C). Furthermore, the expression levels of Ki-67, phospho-AKT, and phospho-STAT3 in xenografted tumors were decreased after CYT-Rx20 treatment (Fig 4D). The mice treated with CYT-Rx20 did not show significant changes in the body weights (S2 Fig), biochemical profiles (S1 Table), and histology of esophagus, heart, liver, lung, spleen, and kidney (Fig 4E) compared with the untreated control mice. In addition, no obvious expression of cleaved caspase-3 was observed in the esophageal epithelium of control or CYT-Rx20-administered mice. Of note, mouse lymph node tissue was used as the positive control to assess the levels of cleaved caspase-3 [28,29] and were depicted in S3 Fig.

Table 1. Cytotoxicity of CYT-Rx20 on esophageal cancer cell lines.

| Cell type         | Cell lines | CYT-Rx20 IC50(b) (μg/ml) | 5-FU IC50(b) (μg/ml) |
|-------------------|------------|--------------------------|----------------------|
| Esophageal cancer | KYSE70     | 5.16 ± 0.21              | 11.71 ± 2.14         |
|                   | TE8        | 3.07 ± 0.04              | 15.45 ± 1.45         |

aThe cells were treated with CYT-Rx20 at different concentrations for 48 h, before proceeding with the XTT assay.

bMeans ± SEM of three independent experiments.
Fig 2. Effect of CYT-Rx20 on KYSE70 and TE8 cell migration and invasion. (A) The effect of CYT-Rx20 on cell migration was detected by using a modified Boyden chamber assay, as described in the Materials and methods section. The representative photographs are shown with ×40 magnification. Histograms represent quantification of cell migration. (B) The effect of CYT-Rx20 on cell invasion was also determined using a modified Boyden chamber assay. Histograms represent quantification of cell invasion. (C) The expression of regulating genes in KYSE70 and TE8 cells treated with different concentrations of CYT-Rx20 was measured using qRT-PCR. The relative expression of each gene was normalized to the expression of GAPDH and expressed as fold change compared to the control.
CYT-Rx20 inhibited orthotopic esophageal tumor growth and metastasis in vivo

To further determine the anti-cancer activity of CYT-Rx20 in vivo, an orthotopic esophageal tumor growth model in nude mice was employed. As shown in Fig 5A, using IVIS Spectrum in vivo imaging system, the mice injected with CYT-Rx20 revealed a significantly lower bioluminescent signal in the abdominal esophagus tissues than the untreated control mice (P < 0.01). CYT-Rx20 treatment did not cause significant changes in biochemical parameters of the mice (S2 Table). Furthermore, the expression of Ki-67 and phospho-STAT3 in orthotopic esophageal tumor tissues were decreased after CYT-Rx20 treatment (Fig 5B), in agreement with our in vitro observation. Finally, similar inhibitory effect of CYT-Rx20 on the expression of Ki-67 and phospho-STAT3 was observed in the metastatic lung tumor tissues (Fig 5C).

Discussion

The β-nitrostyrene family compounds possess diverse biological activities, including induction of cytotoxicity in cancer cells [13,30]. Previous report demonstrated that CYT-Rx20 inhibited breast cancer cell proliferation and tumorigenesis via increase of ROS-mediated MEK/ERK signaling pathway [18]. In this study, we demonstrated for the first time that CYT-Rx20 suppressed the PI3K/AKT and STAT3 signaling pathways and inhibited esophageal cancer cell viability and migration. These results suggested possible tissue-specific anti-cancer activities of CYT-Rx20.

Activation of PI3K/AKT signaling pathway associates with a variety of cellular functions including cell growth, survival, vascular remodeling, angiogenesis, and metastasis [31,32]. Accumulating evidence suggests that suppression of AKT activity is a feasible approach for inhibition of tumor progression [33–35]. In this study, we observed an activation of caspase cascade and PARP cleavage after CYT-Rx20 treatment (Fig 1E), indicating an increased cytotoxicity in esophageal cancer cells. Besides, we also found a reduced migration and invasion in KYSE70 and TE8 cells after CYT-Rx20 treatment (Fig 2), associated with a decreased expression of phospho-p85 and phospho-AKT in esophageal cancer cells (Fig 3A). Therefore, our results provide evidence for the potential application of CYT-Rx20 in esophageal cancer treatment by targeting AKT.

Other than PI3K/AKT signaling network [26], previous reports also demonstrated an essential role of STAT3 [36,37] and its regulation by PI3K/mTOR signaling [38,39] in tumor progression. While a previous study reported the STAT3 mediates PI3K/AKT activation upon interleukin-6 treatment [40,41], our study showed a decreased protein expression of phospho-p85, phospho-AKT, and phospho-STAT3 in esophageal cancer cells after CYT-Rx20 treatment (Fig 3A). Furthermore, pre-treatment of STAT3 activator colivelin followed by CYT-Rx20 decreased the expression of phospho-STAT3, but not phospho-AKT, to a larger extent (data not shown), suggesting that STAT3 functions downstream of AKT. While further efforts are required to resolve this dispute, differential activity of CYT-Rx20 and interleukin-6 on cancer cells can not be ruled out.
Fig 3. Involvement of PI3K/AKT and STAT3 in CYT-Rx20-inhibited KYSE70 and TE8 cell viability and migration. (A) Dose effect of CYT-Rx20 on p85, AKT, and STAT3 phosphorylation was performed by using immunoblotting. KYSE70 and TE8 were incubated with CYT-Rx20, and cell viability was detected by using XTT colorimetric assay. In parallel cultures, cells were pre-treated with 4 μM SC79 (B) or 0.5 μM colivelin (C) for 1 h and were further co-incubated with CYT-Rx20 for another 72 h. All values are expressed as a percentage of the control group, which is set as 100%. Results are means ± SEM (n = 3–4). *P < 0.05, **P < 0.01, ***P < 0.001 compared with the indicated group. Using a modified Boyden chamber assay, KYSE70 and TE8 were pre-treated with 4 μM SC79 (D) or 0.5 μM colivelin (E) for 1 h and further treated with CYT-Rx20 for 48 h.
While CYT-Rx20 treatment inhibited esophageal cancer cell viability, co-treatment with SC79 or colivelin led to a greater reduction in esophageal cancer cell viability, compared with cells only treated with CYT-Rx20 (Fig 3B and 3C). In addition, esophageal cancer cells co-treated with CYT-Rx20 and SC79 (or colivelin) resulted in enhanced decrease in cell migration (Fig 3D and 3E). Oncogene addiction is a phenomenon regarding the dependence of cancer cells on a single activated oncogenic protein or pathway for proliferation and survival [42–45]. For example, the Bcr-Abl inhibitor imatinib selectively induced cytotoxicity in Bcr-Abl-transfected leukemic cells but not Bcr-Abl-negative parental cells [46]. Also, Bcr-Abl mutant-transfected leukemic cells are resistance to the killing by imatinib compared with Bcr-Abl-positive parental cells, suggesting that the cancer cells rely on Bcr-Abl for survival [47]. In another study, treatment of c-MYC-expressing myeloma cells with the 10058-F4 compound, an inhibitor of MYC-MAX heterodimerization, resulted in rapid apoptosis, suggesting that there is an addiction to c-MYC for survival in these cancer cells [48]. There are different types of oncogene addiction according to cellular activities. For example, K-Ras-mediated cancer growth depends on the elevated levels of autophagy (referred to autophagy addiction) [49]. Hall et al. [50] demonstrated that malignant melanoma cells were addicted to V600E BRAF-driven glycolysis for efficient ATP production. Furthermore, our previous data indicated that, while overexpression of Id1 promoted the lung cancer cell growth, treatment of paclitaxel and cisplatin caused a greater reduction on cancer cell growth in the Id1-overexpressing cells, suggesting that lung cancer cells with high Id1 levels may depend on Id1 for survival [51]. Therefore, our current findings suggest that high cellular AKT or STAT3 expression leads esophageal cancer cells to rely on AKT or STAT3 for survival as a result of oncogene addiction.

In this study, the anti-cancer activity of CYT-Rx20 was evaluated in vivo. CYT-Rx20 suppressed xenografted (Fig 4B) and orthotopic (Fig 5A) esophageal tumor growth along with decreased expression of Ki-67, phospho-AKT, and phospho-STAT3 in tumor tissues (Figs 4D and 5B). In addition, we found no obvious impairment of renal or liver functions (S1 and S2 Tables), nor did it cause histological changes in major organs of nude mice including esophagus (Fig 4E), rendering CYT-Rx20 a potentially low side-effect anti-esophageal cancer agent.

Alterations in cell migration, invasion, EMT, and production of matrix metalloproteinase are associated with diverse pathologic changes, such as angiogenesis, restenosis in grafted or injured vessels, and cancer [52–54]. CYT-Rx20 treatment rendered esophageal tumor cells the disability to invade and migrate (Fig 2A and 2B). In agreement with this finding, CYT-Rx20 treatment in an orthotopic esophageal tumor model significantly decreased lung metastasis in mice (Fig 5A and 5C). Furthermore, CYT-Rx20 treatment had an inhibitory effect on cancer cell migration and invasion through activation of epithelial maker (ZO-1) and inactivation of mesenchymal markers (N-cadherin, ZEB1, Slug, Snail) (Fig 2C). EMT is a reversible multistep process defined by the loss of epithelial phenotype and the acquisition of mesenchymal characteristics [55]. For inhibition of cancer cell metastasis, an induction of cell-cell adhesion (characterized by an increase of epithelial cell adhesion proteins including the tight junction proteins, ZO-1 and claudin-1) is required [56]. Lennon et al. [57] demonstrated that STAT3 inhibitor Stattic decreased the opioid and EGF-induced human lung cancer cell proliferation, migration, and EMT transformation (as determined by loss of mesenchymal proteins such as vimentin and the acquisition of epithelial markers including claudin-1). It was also reported that JAK2/STAT3 inhibitor AG490 regulates the activity of EGF on mesenchymal (vimentin and fibronectin) or epithelial (E-cadherin, ZO-1) markers [58]. Park et al. [59] showed that
Fig 4. CYT-Rx20 suppressed xenograft tumor growth and decreased phospho-AKT and phospho-STAT3 expression in vivo. (A) KYSE70 cells were treated with the indicated concentrations of CYT-Rx20, followed by evaluation of anchorage-independent colony formation using soft agar assay as described in the Materials and methods section. The representative photographs are shown with ×100 magnification. (B) Female nude mice subcutaneously xenografted with KYSE70 cells were intraperitoneally treated with 0.1% DMSO in normal saline (control), 5 μg/g CYT-Rx20, or 25 μg/g CYT-Rx20 three times per week (n = 10 for each group). Tumor volumes were measured every week for each group and calculated according to the formula of width^2×length/2. (C) Tumor weight was measured after sacrifice of the mice at the end of the 4-week treatment period. (D) Xenograft tumor tissues were analyzed for the expression of Ki-67, phospho-AKT, and phospho-STAT3 by IHC staining. Negative control was performed in the same procedure but without addition of Ki-67, phospho-AKT, or phospho-STAT3 antibodies. H-score was calculated as the product of percentage of stained cells and intensity of staining. The representative photographs are shown with ×200 magnification. (E) Hematoxylin and eosin (H&E) staining of tissues sections from mouse organs in control and CYT-Rx20 (25 μg/g)-administered mice. The representative photographs are shown with ×100 (Esophagus, Lung, Spleen), ×200 (Heart, Liver, Kidney) magnification. Results are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the control group.

doi:10.1371/journal.pone.0166453.g004
Fig 5. CYT-Rx20 suppressed orthotopic esophageal tumor growth and metastasis in vivo. (A) Luciferase-expressing KYSE70 cells were inoculated into the abdominal esophagus of female nude mice as described in the Materials and methods section. The mice were intraperitoneally injected with 0 μg/g (control) or 5 μg/g of CYT-Rx20 three times a week (n = 4–5 per group). After 4 weeks, the mice were anesthetized and intraperitoneally injected with D-luciferin (150 mg/kg) for detection of bioluminescence by IVIS Spectrum in vivo imaging system. (B) Orthotopic esophageal tumor tissues were analyzed for the expression of Ki-67 and phospho-STAT3 by IHC staining. H-score was calculated as the product of percentage of stained cells and intensity of staining. The representative photographs are shown with ×40 (H&E), ×200 (IHC) magnification. (C) Metastatic lung tumor tissues from mice with or without orthotopic esophageal tumor cell injection were analyzed for the expression of Ki-67 and phospho-STAT3. Histograms show the H-score calculated as the product of percentage of stained cells and intensity of staining. The representative photographs are shown with ×100 (H&E), ×200 (IHC) magnification. Results are means ± SEM. * P < 0.05, ** P < 0.01 compared with the control group.

doi:10.1371/journal.pone.0166453.g005
Sorafenib, a multikinase inhibitor, blocked phospho-STAT3 and then suppressed Epstein-Barr virus-transformed adult retinal pigment epithelial cells through blocking the upregulation of vimentin, Snail, and ZEB1 as well as recovering the expression of ZO-1, claudin-1, and E-cadherin. Inactivation of STAT3-EMT or AKT-EMT axis has been shown to inhibit cancer cell migration [57]. In agreement with this report, we observed inactivation of STAT3-EMT and AKT-EMT axes is responsible for the inhibition of migration and invasion by CYT-Rx20 in vitro and in vivo (Figs 2 and 5C). To the best of our knowledge, this is the first report showing the anti-metastasis activity of CYT-Rx20 on esophageal cancer cells.

In conclusion, CYT-Rx20 inhibited esophageal cancer cell viability and metastasis in vitro and in vivo through down-regulation of AKT and STAT3 activities. Further pre-clinical studies are required to confirm its anti-cancer activity for esophageal cancer.

Supporting Information

S1 Fig. Effect of CYT-Rx20 on cytotoxicity in normal esophageal squamous cells. Normal human esophageal squamous cell line HET-1A was treated with various concentrations of CYT-Rx20 for 48 h and assessed by XTT colorimetric assay. Results are repeated three times with five replicate wells per CYT-Rx20 concentration in each experiment and presented as means ± SEM.

S2 Fig. Effect of CYT-Rx20 on body weight of xenograft tumor mice. Female nude mice subcutaneously xenografted with KYSE70 cells were intraperitoneally treated with normal saline (control), 5 μg/g CYT-Rx20, or 25 μg/g CYT-Rx20 three times per week (n = 10 for each group). Body weights of mice were measured every week for each group. Results are presented as means ± SEM.

S3 Fig. Detection of cleaved caspase-3 in esophageal tissues of control and CYT-Rx20-administered mice. IHC staining for cleaved caspase-3 in esophageal tissue sections in control and CYT-Rx20 (25 μg/g)-administered mice. Mouse axillary lymph node tissues were used as the positive control to assess the levels of cleaved caspase-3. The representative photographs are shown with ×200 (Esophagus), ×400 (lymph node) magnification.

S1 Table. Biochemical profiles of the nude mice after treatment with CYT-Rx20 for 4 weeks.

S2 Table. Biochemical profiles of the orthotopic esophageal cancer mice after treatment with CYT-Rx20 for 4 weeks.

Author Contributions

Conceptualization: WCC YCL YYW CHW YFH CJH PWH SSFY.

Data curation: WCC YCL.

Formal analysis: WCC YCL YHS YYW CHT YAH.

Funding acquisition: SHC SSFY.

Investigation: WCC YHS CHT YAH CHW.
Methodology: WCC YHS YYW CHT.
Project administration: WCC SSFY.
Resources: YYW YFH CJH SHC PWH SSFY.
Supervision: SSFY.
Validation: WCC YCL YHS CHT YAH.
Visualization: WCC YCL SSFY.
Writing – original draft: WCC.
Writing – review & editing: WCC SSFY.

References

1. Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014; 371(26):2499–509. doi: 10.1056/NEJMra1314530 PMID: 25539106
2. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013; 381(9864):400–12. doi: 10.1016/s0140-6736(12)60643-6 PMID: 23734478
3. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003; 349(23):2241–52. doi: 10.1056/NEJMra035010 PMID: 14657432
4. Sjoquist KM, Burmeister BH, Smither s BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011; 12(7):681–92. doi: 10.1016/s1470-2045(11)70142-5 PMID: 21684205
5. Sakaeda T, Yamamori M, Kwahara A, Nishiguchi K. Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Adv Drug Deliv Rev. 2009; 61(5):388–401. doi: 10.1016/j.addr.2008.10.005 PMID: 19135108
6. Carter KC, Finnin YS, Daeid NN, Robson DC, Waddell R. The effect of nitrostyrene on cell proliferation and macrophage immune responses. Immunopharmacol Immunotoxicol. 2002; 24(2):187–97. doi: 10.1081/iph-12003749 PMID: 12066846
7. Rahmani-Nezhad S, Safavi M, Pordeli M, Ardestani SK, Khosravani L, Pourshojaei Y, et al. Synthesis, in vitro cytotoxicity and apoptosis inducing study of 2-aryl-3-nitro-2H-chromene derivatives as potent anti-breast cancer agents. Eur J Med Chem. 2014; 86:562–9. doi: 10.1016/j.ejmech.2014.09.017 PMID: 25216378
8. Pettit RK, Pettit GR, Hamel E, Hogan F, Moser BR, Wolf S, et al. E-Combretastatin and E-resveratrol structural modifications: antimicrobial and cancer cell growth inhibitory beta-E-nitrostyrenes. Bioorg Med Chem. 2009; 17(18):6606–12. doi: 10.1016/j.bmc.2009.07.076 PMID: 19709889
9. He Y, Varadarajan S, Munoz-Planillo R, Burberry A, Nakamura Y, Nunez G. 3,4-methylenedioxy-beta-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 2014; 289(2):1142–50. doi: 10.1074/jbc.M113.515080 PMID: 24265316
10. Hsieh PW, Chang YT, Chuang WY, Shih HC, Chiang SZ, Wu CC. The synthesis and biologic evaluation of anti-platelet and cytotoxic beta-nitrostyrenes. Bioorg Med Chem. 2010; 18(21):7621–7. doi: 10.1016/j.bmc.2010.08.039 PMID: 20850977
11. Wang WY, Hsieh PW, Wu YC, Wu CC. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antplatelet activity. Biochem Pharmacol. 2007; 74(4):601–11. doi: 10.1016/j.bcp.2007.06.001 PMID: 17601492
12. Kaap S, Quentin I, Tamiru D, Shaheen M, Eger K, Steinfelder HJ. Structure activity analysis of the pro-apoptotic, antitumor effect of nitrostyrene adducts and related compounds. Biochem Pharmacol. 2003; 65(4):609–10. PMID: 12566088
13. Park J, Pei D. trans-Beta-nitrostyrene derivatives as slow-binding inhibitors of protein tyrosine phosphatases. Biochemistry. 2004; 43(47):15014–21. doi: 10.1021/bi0486233 PMID: 15554709
14. McNamara YM, Cloonan SM, Knox AJ, Keating JJ, Butler SG, Peters GH, et al. Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents. Bioorg Med Chem. 2011; 19(3):1328–48. doi: 10.1016/j.bmc.2010.11.054 PMID: 21227702
15. Zeng Z, Sun Z, Huang M, Zhang W, Liu J, Chen L, et al. Nitrostyrene Derivatives Act as RXRalpha Ligands to Inhibit TNFalpha Activation of NF-kappaB. Cancer Res. 2015; 75(10):2049–60. doi: 10.1158/0008-5472.can-14-2435 PMID: 25795708

16. Calgarotto AK, da Silva Pereira GJ, Bechara A, Paredes-Gamero EJ, Barbosa CM, Hirata H, et al. Autophagy inhibited Ehrlich ascitic tumor cells apoptosis induced by the nitrostyrene derivative compounds: relationship with cytosolic calcium mobilization. Eur J Pharmacol. 2012; 678(1–3):6–14. doi: 10.1016/j.ejphar.2011.12.031 PMID: 22227332

17. Chen IH, Chang FR, Wu YC, Kung PH, Wu CC. 3,4-Methylenedioxy-beta-nitrostyrene inhibits adhesion and migration of human triple-negative breast cancer cells by suppressing beta1 integrin function and surface protein disulfide isomerase. Biochimie. 2015; 110:81–92. doi: 10.1016/j.bioch.2015.01.006 PMID: 25593085

18. Hung AC, Tsai CH, Hou MF, Chang WL, Wang CH, Lee YC, et al. The synthetic beta-nitrostyrene derivative CYT-Rx20 induces breast cancer cell death and autophagy via ROS-mediated MEK/ERK pathway. Cancer Lett. 2016; 371(2):251–61. doi: 10.1016/j.canlet.2015.11.035 PMID: 26683774

19. Hung AC, Lo S, Hou MF, Lee YC, Tsai CH, Chen YY, et al. Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation. Clin Cancer Res. 2016. doi: 10.1158/1078-0432.ccr-15-2704 PMID: 27036136

20. Chen YJ, Cheng YJ, Hung AC, Wu YC, Tyan YC, et al. The synthetic flavonoid WYC02-9 inhibits cervical cancer cell migration/invasion and angiogenesis via MAPK14 signaling. Gynecol Oncol. 2013; 131(3):734–43. doi: 10.1016/j.ygyno.2013.10.012 PMID: 24145114

21. Kuroda S, Kubota T, Aoyama K, Kikuchi S, Tazawa H, Nishizaki M, et al. Establishment of a Non-Invasive CYT-Rx20 Inhibits Esophageal Tumor Growth and Metastasis Cancer Mouse Model. PLoS One. 2014; 9(12):e114562. doi: 10.1371/journal.pone.0114562 PMID: 25493557

22. Stoyiannik A, Goussia A, Pentheroudakis G, Siozopoulou V, Ioachim E, Krikelis D, et al. Immunohistoch- emical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility. Anticancer Res. 2012; 32(4):1273–81. PMID: 22493359

23. Davies EJ, Dong M, Gutekunst M, Narhi K, van Zoggel HJ, Blom S, et al. Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices. Sci Rep. 2015; 5:17187. doi: 10.1038/srep17187 PMID: 26647838

24. Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol. 2012; 22(5–6):396–403. doi: 10.1016/j.semcancer.2012.04.001 PMID: 22554795

25. Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013; 27 (20):2192–206. doi: 10.1101/gad.253344.113 PMID: 24142872

26. Neiva KG, Zhang Z, Miyazawa M, Warner KA, Karl E, Nor JE. Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia. 2009; 11(6):583–93. PMID: 19484147

27. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000; 19(18):2474–88. doi: 10.1038/sj.onc.1203527 PMID: 10851046

28. Takahashi Y, Hori T, Cooper TK, Liao J, Desai N, Serfass JM, et al. Bif-1 haploinsufficiency promotes chromosomal instability and accelerates Myc-driven lymphomagenesis via suppression of mitophagy. Blood. 2013; 121(9):1622–32. doi: 10.1182/blood-2012-10-459826 PMID: 23287860

29. Engel K, Rudelius M, Slawska J, Jacobs L, Ahangarian Abhari B, Altmann B, et al. USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma. EMBO Mol Med. 2016; 8(8):851–62. doi: 10.15252/emmm.201506047 PMID: 27317434

30. Milhazes N, Calheiro R, Marques MP, Garrido J, Cordeiro MN, Rodrigues C, et al. Beta-nitrostyrene derivatives as potential antibacterial agents: a structure-property-activity relationship study. Bioorg Med Chem. 2006; 14(12):4078–88. doi: 10.1016/j.bmc.2006.02.006 PMID: 16497504

31. Yang SX, Polley E, Lipkowitz S. New insights on PI3K/AKT/mTOR pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev. 2016; 45:87–96. doi: 10.1016/j.ctrv.2016.03.004 PMID: 26995633

32. Li B, Cheung PY, Wang X, Tsoa SW, Ling MT, Wong YC, et al. Id-1 activation of PI3K/Akt/NFkB signaling pathway and its significance in promoting survival of esophageal cancer cells. Carcinogenesis. 2007; 28(11):2313–20. doi: 10.1093/carcin/bgm152 PMID: 17638919

33. Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets. 2009; 9(2):237–49. PMID: 19275762

34. Beck JT, Ismail A, Tolomeo C. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma. Cancer Treat Rev. 2014; 40(8):980–9. doi: 10.1016/j.ctrv.2014.06.006 PMID: 25037117
35. Ku GY, Ilson DH. Esophagogastroduodenal cancer: targeted agents. Cancer Treat Rev. 2010; 36(3):235–48. doi: 10.1016/j.ctrv.2009.12.009 PMID: 20122806

36. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002; 8(4):945–54. PMID: 11948098

37. Masuda M, Ruan HY, Ito A, Nakashima T, Toh S, Wakisaka T, et al. Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma. Oral Oncol. 2007; 43(8):785–90. doi: 10.1016/j.oraloncology.2006.10.007 PMID: 17169602

38. Yokogami K, Wakisaka S, Avruch J, Reeves SA. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol. 2000; 10(1):47–50. PMID: 10660304

39. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, et al. Activation of the PTEN/mTOR/STAT3 pathway in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways. Oncogene. 2004; 23(19):3368–75. doi: 10.1038/sj.onc.1207459 PMID: 15021914

40. Lee YJ, Heo JS, Suh HN, Lee MY, Han HJ. Interleukin-6 stimulates alpha-MG uptake in renal proximal tubule cells: involvement of STAT3, PI3K/Akt, MAPKs, and NF-kappaB. Am J Physiol Renal Physiol. 2007; 293(4):F1036–46. doi: 10.1152/ajprenal.00034.2007 PMID: 17581928

41. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008; 68(9):3077–80; discussion 80. doi: 10.1158/0008-5472.can-07-3293 PMID: 18451130

42. Blagosklonny MV. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget. 2011; 2(12):1352–67. doi: 10.18632/oncotarget.432 PMID: 22267462

43. Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420–8. doi: 10.1172/jci39104 PMID: 19487618

44. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010; 101(2):293–9. doi: 10.1111/j.1349-7006.2009.01419.x PMID: 19961486

45. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005; 438(7070):967–74. doi: 10.1038/nature04483 PMID: 16355214

46. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005; 436(7050):518–24. doi: 10.1038/nature03799 PMID: 16049480

47. Li B, Tsao SW, Li YY, Wang X, Ling MT, Wong YC, et al. High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients. Oncotarget. 2014; 5(22):11564–75. doi: 10.18632/oncotarget.25344919

48. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005; 438(7070):967–74. doi: 10.1038/nature04483 PMID: 16355214

49. Li B, Tsao SW, Li YY, Wang X, Ling MT, Wong YC, et al. High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients. Oncotarget. 2014; 5(22):11564–75. doi: 10.18632/oncotarget.25344919

50. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005; 438(7070):967–74. doi: 10.1038/nature04483 PMID: 16355214

51. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005; 436(7050):518–24. doi: 10.1038/nature03799 PMID: 16049480

52. Li B, Tsao SW, Li YY, Wang X, Ling MT, Wong YC, et al. High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients. Oncotarget. 2014; 5(22):11564–75. doi: 10.18632/oncotarget.25344919
57. Lennon FE, Mirzapoiozova T, Mambetsariev B, Poroyko VA, Salgia R, Moss J, et al. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; 9(3):e91577. doi: 10.1371/journal.pone.0091577 PMID: 24662916

58. Verma N, Keinan O, Selitrennik M, Karn T, Filipits M, Lev S. PYK2 sustains endosomal-derived receptor signalling and enhances epithelial-to-mesenchymal transition. Nat Commun. 2015; 6:6064. doi: 10.1038/ncomms7064 PMID: 25648557

59. Park GB, Kim D, Kim YS, Kim JW, Sun H, Roh KH, et al. Regulation of ADAM10 and ADAM17 by Sorafenib Inhibits Epithelial-to-Mesenchymal Transition in Epstein-Barr Virus-Infected Retinal Pigment Epithelial Cells. Invest Ophthalmol Vis Sci. 2015; 56(9):5162–73. doi: 10.1167/iovs.14-16058 PMID: 26244291